Fig. 1.
Study overview. As recently published in Cell, Mucker et al. conducted an mpox vaccine study in non-human primates (NHP), comparing a novel mRNA vaccine (mRNA-1769) to a live-attenuated Modified Vaccinia virus Ankara (MVA) vaccine. Following vaccination, NHPs were challenged with the mpox virus. While vaccination with mRNA-1769 and MVA resulted in similar protection against lethality, mRNA-1769 vaccination led to a stronger reduction of mpox lesions and viremia and induced superior antibody titers and functionality. A multivariate correlates analysis revealed that neutralizing and Fc-mediated antibody functions were associated with vaccine-induced protection. Created in BioRender